Hypericin

Polycyclic dione that has anti-retroviral activity. Inhibits protein kinase C (IC₅₀ = 3.3 µM). Also known to inhibit the protein tyrosine kinase activities of the insulin receptor (IC₅₀ = 20-29 nM), the epidermal growth factor receptor (IC₅₀ = 35 nM), casein kinase II (IC₅₀ = 6 nM), and MAP kinase (IC₅₀ = 4 nM). Useful probe for PKC due to its bright red fluorescence emission and photostability. Also see Pseudohypericin (Cat. No. 539590).

Polycyclic dione that has anti-retroviral activity. Inhibits protein kinase C (IC₅₀ = 3.3 μM). Also known to inhibit casein kinase II (IC₅₀ = 6 nM), MAP kinase (IC₅₀ = 4 nM), and the protein tyrosine activities of the insulin receptor (IC₅₀ = 20-29 nM) and the epidermal growth factor receptor (IC₅₀ = 35 nM).

Primary Target
PKC

Target IC₅₀: 3.3 µM, 6 nM, 4 nM, 20-29 nM , 35 nM, against protein kinase C, casein kinase II, MAP kinase, the protein tyrosine activities of the insulin receptor, and the epidermal growth factor receptor, respectively

Toxicity: Harmful (C)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Zhang, W., et al. 1997. Cancer Lett.120, 31.
Agostinis, P., et al. 1995. Biochem. Pharmacol.49, 1615.
Frew, T., et al. 1994. Anticancer Res.14, 2425.
Barnard, D.L., et al. 1992. Antiviral Res.17, 63.
Takahashi, I., et al. 1989. Biochem. Biophys. Res. Commun.165, 1207.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany